CN202191582U - Medicine balloon dilating catheter - Google Patents
Medicine balloon dilating catheter Download PDFInfo
- Publication number
- CN202191582U CN202191582U CN2011202338175U CN201120233817U CN202191582U CN 202191582 U CN202191582 U CN 202191582U CN 2011202338175 U CN2011202338175 U CN 2011202338175U CN 201120233817 U CN201120233817 U CN 201120233817U CN 202191582 U CN202191582 U CN 202191582U
- Authority
- CN
- China
- Prior art keywords
- medicine
- balloon
- sacculus
- outer tube
- dilating catheter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The utility model discloses a medicine balloon dilating catheter, which comprises a balloon, an inner tube, an outer tube, a tip and medicine coatings; the balloon is sleeved to the inner tube; one end of the balloon is connected with the tip, while the other end of the balloon is connected with the outer tube; and the medicine coatings are disposed on the outer surfaces of the balloon and the outer tube respectively. The compound medicine for the medicine balloon dilating catheter can resist neointimal hyperplasia, inflammation and thrombus; the medicine carried by the balloon is remained on the lesion part, so that the blood vessel can be kept unblocked while being dilated; and potential safety hazard resulted from inhibition effect of polymer carrier on the DES surface on endothelial cell repairing and healing process is completely removed.
Description
Technical field
The utility model relates to a kind of medical sacculus dilating catheter, in particular a kind of medicinal balloon dilating catheter.
Background technology
(percutaneous coronary intervention, PCI) technology is mainly used in treatment coronary heart disease and myocardial ischemia such as angina pectoris, myocardial infarction etc. to interventional therapy in the percutaneous coronary artery angiography.Laying support in the coronary artery is the main mode of present PCI.PCI can alleviate coronary heart disease patient's symptom, improves coronary heart disease patient's prognosis, reduces the incidence rate of cardiovascular event and sudden cardiac death, reduces the mortality rate of acute myocardial infarction.Restenosis is the main factor that influences the PCI curative effect behind the PCI.(Drug-eluting Stent DES) can reduce the incidence rate of restenosis behind the PCI to bracket for eluting medicament, but can not eliminate the generation of restenosis behind the PCI fully.Restenosis behind the prevention PCI, promote that atheromatous plaque reverses, the treatment endstage cardiac insufficiency is 3, most worthies the most great in the present cardiovascular field, the most urgent problem.
The major programme of restenosis is behind the prevention PCI at present: lay DES, radiotherapy and Drug therapy.Drug therapy be behind the prevention PCI restenosis the most directly, the easiest method.Slowly discharge the influence that medicine then receives medicine dissolution property, dispersivity, release dynamics, local concentration, Local Residence Time etc. through DES.Owing to lay the main method that support is present PCI in the coronary artery, the mechanism of restenosis will be studied the mechanism of laying restenosis behind the support in the coronary artery behind the research PCI.
(percutaneous transluminal coronary angioplasty, PTCA) mechanism of back restenosis is slightly different for the machine-processed same PTCA of in-stent restenosis.Restenosis is early stage relevant with blood vessel elasticity retraction, blood vessel wall dissecting aneurysm behind the PTCA, and subacute stage is relevant with thrombosis, late period then with vascular smooth muscle cell proliferation, move relevant.The introducing of support has avoided fully because blood vessel elasticity retraction, blood vessel wall dissecting aneurysm restenosis of caused drought period, and the instant curative effect of laying behind the support is guaranteed.Because it is the chronic stimulation to blood vessel wall that support retains on the blood vessel wall for a long time, for utilizing support slowly to throw in medicine probability is provided again.The essence of in-stent restenosis is a kind of over-drastic healing reaction of body to damage.In laying the support process, the support after seal wire operation, balloon expandable, the expansion itself all causes damage to blood vessel wall inevitably.Support after the expansion partly embeds blood vessel wall, especially to a kind of lasting stimulation and the damage of blood vessel wall.On the blood vessel wall that support covered, part is normally or still normal vascular endothelial cell, and part is an atheromatous plaque.Lay the support process normal vascular endothelial cell is sustained damage, make collagen tissue exposure under its inner membrance, cause private agglomeration collection of platelet and thrombosis.Lay the support process and make also that atheromatous plaque breaks, disintegrate, medicated porridge appearance material exposes.Said process causes that all inflammatory cell infiltration, oxygen-derived free radicals produce.Activated platelet can be secreted palatelet-selectin (P-selectin), and palatelet-selectin can make neutrophilic granulocyte attach to platelet.Lay the inflammatory process that causes behind the support and more be far more than PTCA.At the same time, various MFs such as fibroblast growth factor, platelet-derived growth factor, transferinggrowthingfactor etc. are a large amount of to be produced, and stimulated vascular smooth muscle cell is bred and shifted under tunica intima by the media.The blood vessel epimatrix also produces in a large number.New tunica intima mainly is made up of VSMC (being called fibroblast after transferring under the tunica intima), macrophage and blood vessel epimatrix.This new tunica intima can be grown in support by blood vessel and support intersection (bracket edge), also can in support, be grown by the hole of support.
The utility model content
The utility model purpose: this utility model provides a kind of medicinal balloon dilating catheter, can smoothly medicine be sent to diseased region, the various inflammation of having avoided present use support to be brought simultaneously.
Technical scheme: this utility model comprises sacculus, interior pipe, outer tube, top and medication coat; Wherein: sacculus is on inner pipe sheathed, and an end of sacculus links to each other with top, and the other end of sacculus links to each other with outer tube, and medication coat is arranged at the outer surface of sacculus and outer tube respectively.
In order to realize that the more efficiently of medicine carried, said sacculus is provided with 2～3 flaps, after medication coat is coated in the sacculus outer surface, on sacculus, does flap, can make coating medicine coating in the flap.
Sacculus is delivered to lesion locations, and dilating sacculus makes the medicine that carries on the sacculus be docked to diseased region, plays blood vessel dilating and keeps unimpeded period, when the lesion vessels restenosis stops up, also can carry out the secondary treatment through secondary medicine carrying sacculus.
Said medication coat adopts the lipotropy IK 35760 to make carrier, and medicine is the combination drug of anti-neointimal hyperplasia, antithrombotic and anti-inflammatory.
Beneficial effect: this utility model is compared prior art and had the following advantages: the combination drug of this utility model can resist neointimal hyperplasia, anti-inflammatory and antithrombotic; The medicine that carries on the sacculus is docked to diseased region, in blood vessel dilating, keeps unimpeded; Adopt lipophilic carriers, thoroughly eliminate because the potential safety hazard that the polymer support on DES surface brings the inhibitory action in endotheliocyte reparation and the agglutination.
Description of drawings
Fig. 1 is the structural representation of this utility model.
The specific embodiment
Embodiment in the face of this utility model elaborates down; Present embodiment is being to implement under the prerequisite with this utility model technical scheme; Provided detailed embodiment and concrete operating process, but the protection domain of this utility model is not limited to following embodiment.
As shown in Figure 1, present embodiment comprises sacculus 1, interior pipe 2, outer tube 3, top 4, Marking ring 5 and medication coat 6; Medication coat 6 is arranged at the outer surface of sacculus 1 and outer tube 3 respectively; On the pipe 2, an end of sacculus 1 linked to each other with top 4 in sacculus 1 was set in, and the other end of sacculus 1 links to each other with outer tube 3; One end of interior pipe 2 links to each other with top 4; The other end of interior pipe 2 links to each other with catheter block, and outer tube 3 links to each other with catheter block, and Marking ring 5 is fixed on the interior pipe 2 and is positioned at sacculus 1; Catheter block is provided with two inner chambers that do not communicate, pipe 2 and outer tube 3 in being used for being communicated with respectively.
In order to realize that the more efficiently of medicine carried, be provided with 3 flaps at sacculus 1, medication coat 6 is done flap after being coated in sacculus 1 outer surface on sacculus 1, can make coating medicine coating 6 in the flap.Medication coat 6 adopts the lipotropy IK 35760 to make carrier, and medicine is the combination drug of anti-neointimal hyperplasia, antithrombotic and anti-inflammatory.
Sacculus 1 can make the medicine that carries on the sacculus 1 be docked to diseased region through the pressurization expansion through lesion locations such as calcify lesion the time, keep when reaching blood vessel dilating unimpeded treatment coronary artery, artery of lower extremity narrow, block and the purpose of other angiopathys.
Claims (3)
1. a medicinal balloon dilating catheter is characterized in that, comprises sacculus (1), interior pipe (2), outer tube (3), top (4) and medication coat (6); Wherein: sacculus (1) is set on the interior pipe (2), and an end of sacculus (1) links to each other with top (4), and the other end of sacculus (1) links to each other with outer tube (3), and medication coat (6) is arranged at the outer surface of sacculus (1) and outer tube (3) respectively.
2. medicinal balloon dilating catheter according to claim 1 is characterized in that: said sacculus (1) is provided with 2～3 flaps.
3. medicinal balloon dilating catheter according to claim 1 is characterized in that: pipe (2) is provided with Marking ring (5) in said, and said Marking ring (5) is positioned at sacculus (1).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011202338175U CN202191582U (en) | 2011-07-05 | 2011-07-05 | Medicine balloon dilating catheter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011202338175U CN202191582U (en) | 2011-07-05 | 2011-07-05 | Medicine balloon dilating catheter |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202191582U true CN202191582U (en) | 2012-04-18 |
Family
ID=45946515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011202338175U Expired - Fee Related CN202191582U (en) | 2011-07-05 | 2011-07-05 | Medicine balloon dilating catheter |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202191582U (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103949006A (en) * | 2014-04-15 | 2014-07-30 | 上海市第六人民医院 | Coronary artery dilating catheter carrying ligustrazine nanoparticles |
| CN103949003A (en) * | 2014-05-12 | 2014-07-30 | 辽宁生物医学材料研发中心有限公司 | Expanding continuous-flow balloon catheter and preparation method thereof |
| CN104001258A (en) * | 2014-03-21 | 2014-08-27 | 深圳脉动医学技术有限公司 | Repair type balloon catheter |
| CN105288823A (en) * | 2015-11-27 | 2016-02-03 | 王显 | Drug eluting balloon system |
| CN110151366A (en) * | 2012-12-31 | 2019-08-23 | 明讯科技有限公司 | Foley's tube with transient state radiopaque label |
-
2011
- 2011-07-05 CN CN2011202338175U patent/CN202191582U/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110151366A (en) * | 2012-12-31 | 2019-08-23 | 明讯科技有限公司 | Foley's tube with transient state radiopaque label |
| CN110151366B (en) * | 2012-12-31 | 2022-02-08 | 明讯科技有限公司 | Balloon catheter with transient radiopaque markings |
| US11491308B2 (en) | 2012-12-31 | 2022-11-08 | Clearstream Technologies Limited | Balloon catheter with transient radiopaque marking |
| CN104001258A (en) * | 2014-03-21 | 2014-08-27 | 深圳脉动医学技术有限公司 | Repair type balloon catheter |
| CN103949006A (en) * | 2014-04-15 | 2014-07-30 | 上海市第六人民医院 | Coronary artery dilating catheter carrying ligustrazine nanoparticles |
| CN103949003A (en) * | 2014-05-12 | 2014-07-30 | 辽宁生物医学材料研发中心有限公司 | Expanding continuous-flow balloon catheter and preparation method thereof |
| CN105288823A (en) * | 2015-11-27 | 2016-02-03 | 王显 | Drug eluting balloon system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN202191582U (en) | Medicine balloon dilating catheter | |
| CN101365447A (en) | Pharmaceuticals compositions containing nanomaterials useful for treating restenotic lesions | |
| WO2015070814A1 (en) | Drug-eluting balloon and preparation method therefor | |
| JP5777607B2 (en) | H-side branch vessel stent | |
| CN202113470U (en) | Medicament sac catheter with anti-slippage function | |
| CN204050424U (en) | A kind of medicinal balloon | |
| CN101264345A (en) | Degradable blood vessel stent drug-eluting capable of reducing incidence rate of advanced thrombus | |
| CN101485902B (en) | Biological degradable metal stent coated with rapamycin-probucol composite medicament | |
| CN101007187B (en) | Preparation method of composite drug-eluting stent and its drug coated layer | |
| CN101239216A (en) | Novel sacculus dilating catheter | |
| CN209137002U (en) | A kind of medicinal balloon | |
| CN106618821B (en) | A kind of intravascular stent for preventing reangiostenosis and preparation method thereof | |
| CN201179222Y (en) | Medicament coating bracket | |
| CN105853036B (en) | A kind of degradable personalized bionical medicament elution coronary stent of non-columnar | |
| CN202146455U (en) | Cardiovascular composite medicine bracket | |
| WO2018059207A1 (en) | New use of amlexanox | |
| CN205698633U (en) | A kind of bracket for eluting medicament | |
| CN107106309B (en) | Bracket for eluting medicament | |
| JP2022078154A (en) | Medicament eluting type stent | |
| CN202740163U (en) | Cardiovascular medicament coating rack | |
| CN201453424U (en) | Cardiovascular composite coating drug eluting stent | |
| CN203915574U (en) | Containing composite coating support in the blood vessel of Thalidomide layer | |
| CN201847800U (en) | Biodegradable drug-coated support for coronary artery | |
| Zeng et al. | Stent and Perfusion Balloon | |
| CN204909753U (en) | Assist and to absorb spraying lining structure that support carries out medicine spraying |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: PULIRUI MEDICAL TECHNOLOGY (SUZHOU) CO., LTD. Free format text: FORMER OWNER: KEMING TECHNOLOGY (HK) CO., LTD. Effective date: 20120801 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: HONG KONG, CHINA TO: 215123 SUZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120801 Address after: Xinghu street Suzhou Industrial Park in Jiangsu province 215123 No. 218 building 201 room C9 Patentee after: Pulirui medical technology (Suzhou) Co., Ltd. Address before: Liberty No. 50 Hongkong Kowloon Road China center 21 Kwun Tong source building room 2106 Patentee before: Colmee Technology (Hongkong) Co. Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120418 Termination date: 20140705 |
|
| EXPY | Termination of patent right or utility model |